Barclays
COGT icon

Barclays’s Cogent Biosciences COGT Stock Holding History

Barclays’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-79,000
Closed -$567K – 5520
2025
Q2 		$567K Buy
+79,000
New +$438K ﹤0.01% 3693

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Barclays's COGT Position: Q3 2026 in Review

Barclays increased its Cogent Biosciences (COGT) stake by 354% in Q3 2026, buying an estimated $6.28M and bringing the position to 217,977 shares worth $6.98M. The position accounts for ﹤0.01% of the portfolio, ranked #1862.

Barclays first reported a position in COGT in Q2 2018 and has held it in 26 quarters since. The position peaked at $11.4M in Q4 2025. 202 funds tracked by Wall St. Rank hold COGT as of Q3 2026.

  • Barclays held 217,977 shares of Cogent Biosciences worth $6.98M as of Q3 2026.
  • Barclays bought 170,014 Cogent Biosciences shares in Q3 2026, an estimated $6.28M.
  • Cogent Biosciences made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1862 holding.
  • Barclays first reported a position in Cogent Biosciences in Q2 2018 and has held it in 26 quarters since.
  • Barclays's Cogent Biosciences position peaked at $11.4M in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.